The Expression of Serum LCN2 and LTBP2 in Ovarian Cancer patients and Their Relationship with Clinicopathological Features and Prognosis
10.12259/j.issn.2095-610X.S20250714
- VernacularTitle:卵巢癌患者血清LCN2、LTBP2表达及其与临床病理特征和预后的关系
- Author:
Jiao DANG
1
;
Na WANG
;
Linyu HAN
Author Information
1. 西安医学院附属宝鸡医院病理科,陕西 宝鸡 721006
- Keywords:
Ovarian cancer;
Lipocalin-2;
Latent transforming growth factor-β binding protein 2;
Clinicopathological features;
Prognosis
- From:
Journal of Kunming Medical University
2025;46(7):118-124
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the expression of serum lipocalin-2(LCN2)and latent transforming growth factor-β binding protein 2(LTBP2)in ovarian cancer patients and their relationship with clinicopathological features and prognosis.Methods A total of 108 ovarian cancer patients treated in Baoji Hospital Affiliated to Xi'an Medical College from February 2020 to December 2021 were included in the ovarian cancer group.Another 108 patients with benign ovarian lesions during the same period were included and labeled as the lesion group,and 108 healthy female volunteers undergoing physical examination were assigned to the control group.ELISA method was used to detect serum LCN2 and LTBP2 levels.The relationship between serum LCN2 and LTBP2 levels and prognosis survival rate in ovarian cancer patients was analyzed using the Kaplan-Meier method.Multivariate Cox regression analysis was performed to identify the risk factors affecting the prognosis of ovarian cancer patients.Results Serum LCN2 and LTBP2 levels increased in the control group,lesion group,and ovarian cancer group in sequence(P<0.05).Among patients with high expression of serum LCN2 and LTBP2,the proportions of FIGO stage Ⅲ-Ⅳ,tumor maximum diameter>3 cm,and postoperative lymph node metastasis were higher than those of FIGO stages Ⅰ-Ⅱ,tumor maximum diameter≤3 cm,and non lymph node metastasis(P<0.05).The median survival time of ovarian cancer patients with high serum LCN2 and LTBP2 expression was lower than that of patients with low expression(Log-rank χ2=5.367、6.305,P<0.05).The survival rate of patients with FIGO stage Ⅲ～Ⅳ,maximum tumor diameter>3 cm,postoperative lymph node metastasis,LCN2 and LTBP2 high expression was lower than that of patients with FIGO stage Ⅰ～Ⅱ,tumor maximum diameter≤3 cm,no postoperative lymph node metastasis,and low LCN2 and LTBP2 expression(P<0.05).FIGO stages Ⅲ-Ⅳ,maximum tumor diameter>3 cm,postoperative lymph node metastasis,high LCN2,and high LTBP2 were independent risk factors affecting the 3-year survival rate of ovarian cancer patients(P<0.05).Conclusion Serum LCN2 and LTBP2 are upregulated in ovarian cancer patients,and are closely related to FIGO staging,tumor maximum diameter,and postoperative lymph node metastasis.They are important factors affecting prognosis and may serve as biomarkers for evaluating prognosis.
